Lancet : January 2026, REGENECYTE cord blood cell therapy in post-COVID syndrome: a phase IIa randomized, placebo-controlled trial

This clinical study investigates a pioneering medical treatment called REGENECYTE, which utilizes umbilical cord blood cells to combat the persistent exhaustion associated with long COVID. By administering multiple intravenous infusions to a small group of patients, researchers discovered that this allogeneic progenitor cell therapy was not only safe but also led to a significant and lasting reduction in physical fatigue. Participants receiving the treatment reported a meaningful boost in their overall quality of life and mental well-being compared to those who received a placebo. Ultimately, these findings suggest that regenerative cell-based therapiesoffer a promising new strategy for managing the most debilitating symptoms of post-viral syndromes.